• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Bangalore, Aug. 8

Strides Arcolab said it has received its first ANDA approval from Canadian regulator Health Canada for its advanced anti-nausea drug, Ondansetron injection 2 mg/ml. Strides has licensed the product to an undisclosed partner in Canada and expects to begin sales in the last quarter of 2007, a release said. Ondansetron, used against general and chemotherapy-induced nausea, is the first of various sterile submissions the company has submitted to Health Canada. Mr Arun Kumar, V ice-Chairman and Managing Director of Strides Arcolab, said the first Canadian approval for an important sterile product was another milestone in creating a global sterile injectable business. – Our Bureau

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Allergan opens R&D centre in Bangalore

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line